Benefits
Mood support: self-rated low mood improved in placebo-controlled trials
A recent meta-analysis of 34 placebo-controlled trials found lower self-rated depression and anxiety scores with saffron, but clinician-rated scales did not differ from placebo. Several small trials in people diagnosed with depression also compared saffron with prescription antidepressants; they do not establish equivalence, and saffron is not a substitute for medication.
Premenstrual symptoms and mood in women
In a double-blind trial, women with premenstrual symptoms who took saffron 15 mg twice daily for two cycles had lower daily symptom and depression rating scores than placebo. A recent meta-analysis pooling this and other small trials, most run in Iran, also found lower premenstrual symptom scores with saffron; one included study had no placebo group.
Postmenopausal mood support
In a placebo-controlled trial of 60 postmenopausal women with hot flashes and depression, saffron 30 mg/day for 6 weeks improved clinician-rated depression scores and hot flash interference ratings more than placebo. A separate unblinded trial of daily saffron tea in 72 postmenopausal women reported higher happiness scores. These are small trials that need confirmation.
Occasional anxiety: self-rated scores improved in pooled trials
Pooled placebo-controlled trials report lower anxiety scores with saffron. One meta-analysis found a large effect but also evidence of publication bias; a newer one found self-rated anxiety scores improved while clinician-rated anxiety scales showed no significant change. Saffron is not a substitute for care of a diagnosed anxiety disorder.
Retinal function: early findings from a small trial
In a small trial of 25 people with early AMD, saffron 20 mg/day for 3 months raised retinal flicker responses on electroretinogram testing compared with placebo. A follow-up of 29 patients by the same group reported the gains held over about 14 months, but it had no placebo group. This is research in a patient population; clinical significance is not yet established, and saffron is not a substitute for eye care.
Snacking and satiety: one small trial of a branded extract
In one 8-week placebo-controlled trial of 60 mildly overweight women, a branded saffron extract (Satiereal, 176.5 mg a day) reduced snacking frequency and produced greater body weight loss than placebo, with calorie intake unrestricted. Because this is a single small trial of a different branded product, its results may not apply to generic saffron extracts.
Cognitive scores in one placebo-controlled patient trial
In one 16-week placebo-controlled trial of 46 people with probable mild-to-moderate Alzheimer's disease, saffron 30 mg/day gave better scores than placebo on cognitive and dementia rating scales. This single trial was in a patient population and is not evidence that saffron treats the disease or enhances cognition in healthy adults; any use alongside medical care should be directed by the treating clinician.
Product quality: choose a standardized extract
Saffron is costly and product quality varies. The trials on this page used specific saffron stigma preparations or branded extracts, so choose a product that states its saffron source and standardization and is third-party tested.
Better sleep quality in adults with poor sleep
A meta-analysis of saffron trials found better sleep quality scores than placebo (PSQI 2.14 points lower), but a second review rated that evidence very low certainty, so the true effect is uncertain. The key trials gave the branded affron extract (14 mg twice daily, or 14 to 28 mg at bedtime) for 28 days to 63 and 120 adults with poor sleep, measured sleep by self-report, and the first was funded by the maker.
Mechanism of action
Serotonin and dopamine signaling (animal research)
In mice, a branded saffron extract reduced depressive-like behavior and changed serotonin and dopamine neurotransmission. A systematic review lists serotonergic effects among possible explanations for the mood findings in trials. How saffron acts in humans has not been established.
Antioxidant, anti-inflammatory and stress-hormone pathways (proposed)
A systematic review of saffron and mood proposed antioxidant, anti-inflammatory, neuroendocrine and neuroprotective effects as further possible mechanisms, based on animal and cell studies. None has been confirmed as the reason for the effects seen in human trials.
Retinal carotenoids crocin and crocetin
Saffron contains the antioxidant carotenoids crocin and crocetin. The authors of the early AMD trial noted that the retinal function changes may involve effects beyond antioxidant activity. How saffron acts in the human retina has not been established.
Clinical trials
6-week double-blind randomized pilot trial of saffron capsules 30 mg/day (three doses) versus imipramine 100 mg/day, with no placebo group (Akhondzadeh et al. 2004, BMC Complement Altern Med).
30 adult outpatients diagnosed with major depression (baseline Hamilton depression score of at least 18)
The authors reported saffron was effective, and the difference between groups was not statistically significant (P = 0.09). Dry mouth and sedation were seen more often with imipramine. A non-significant difference in a 30-person pilot does not show equivalence to a medication, and saffron is not a substitute for prescribed treatment.
6-week double-blind randomized trial of saffron 60 mg/day versus sertraline 100 mg/day, with no placebo group (Ahmadpanah et al. 2019, Psychiatry Res).
50 older outpatients diagnosed with major depressive disorder (mean age about 65, 70% men)
Clinician-rated depression scores (Hamilton scale) fell over time in both groups, with no advantage for either. Without a placebo group the trial cannot show how much of the change was due to saffron, and it does not establish equivalence to medication; saffron is not a substitute for prescribed treatment. This trial used twice the usual 30 mg dose.
GRADE-assessed systematic review and meta-analysis of 34 randomized trials lasting at least 4 weeks in which saffron was the only difference between groups (Mahmoudi et al. 2026, Nutr Neurosci).
1,769 adults across the included trials
Saffron lowered self-rated depression scores (Beck Depression Inventory, 14 trials, mean difference -4.39 points) and self-rated anxiety scores (Beck Anxiety Inventory, 6 trials, -5.06 points), with very high heterogeneity. Clinician-rated scales (HDRS, HARS) and the POMS mood scale showed no significant effect. The authors rated certainty as moderate and called for higher-quality trials.
Randomized placebo-controlled crossover trial: saffron 20 mg/day or placebo for 3 months, then switched for a further 3 months (Falsini et al. 2010, Invest Ophthalmol Vis Sci).
25 patients with early age-related macular degeneration
After saffron, focal electroretinogram amplitude rose (mean change 0.25 log microvolts versus -0.003 after placebo, P < 0.01) and flicker thresholds fell, indicating improved retinal flicker sensitivity. The authors noted the results need replication and their clinical significance has yet to be evaluated.
8-week randomized double-blind placebo-controlled trial of the branded saffron extract Satiereal, 176.5 mg/day taken as one capsule twice daily (Gout et al. 2010, Nutr Res).
60 healthy, mildly overweight women
Body weight fell more with Satiereal than placebo (P < .01), and snacking frequency, recorded in a daily diary as the main secondary outcome, decreased more than with placebo (P < .05), with calorie intake unrestricted. Other body measurements were almost unchanged. This is one small trial of a branded product; it has not been confirmed for generic saffron.
6-week randomized trial, not blinded, of one cup of tea daily made from 30 mg dried saffron stigmas versus lukewarm water with rock candy (Delam et al. 2023, BMC Complement Med Ther).
72 postmenopausal women in Iran
Oxford Happiness Questionnaire scores rose from 42.93 to 61.58 in the saffron tea group and did not change in the control group; the difference between groups was significant (P < 0.001). Participants could not be blinded to which drink they received, which limits a self-rated outcome.
6-week double-blind randomized placebo-controlled trial of saffron 30 mg/day, taken as 15 mg twice daily (Kashani et al. 2018, Arch Gynecol Obstet).
60 postmenopausal women with hot flashes and major depressive disorder; 56 completed
Compared with placebo, saffron produced greater improvement over time on the Hot Flash-Related Daily Interference Scale and the clinician-rated Hamilton Depression Rating Scale. Adverse events were not significantly more frequent than with placebo. This is research in a diagnosed population and does not show saffron is a substitute for medical care.
Open-label longitudinal study with no placebo group: saffron 20 mg/day for an average of 14 months (Piccardi et al. 2012, Evid Based Complement Alternat Med).
29 patients with early age-related macular degeneration, aged 55 to 85
After 3 months, retinal flicker sensitivity improved by 0.3 log units and visual acuity by about two Snellen lines from baseline, and these changes were still present at later visits. Without a control group, the study cannot confirm long-term benefit or safety.